Navigation Links
Journal of Opioid Management Welcomes New Editor-in-Chief!
Date:1/30/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...lar drugs do not cause genetic damage that can lea...Day News) -- Two popular medications for treating ... not cause genetic damage linked to an increased r...The study, done by researchers at Duke University ...th, counters a previous one that reported biomarke...
(Date:11/21/2008)...ew and deadly diseaseits cause remains a mysterysw...eeming with citizens, soldiers and refugees of the...eets filled with corpses, social order broke down....wice and Athens lost a third of its population. It... beginning of the end of the Golden Age of Greece....
(Date:11/21/2008)... /PRNewswire/ -- For the second year in a row an...Healthcare Worldwide,s agency network won more cre...22nd annual international RX Club Show. , , ...won a total of 59 RX Club Awards of Excellence, in...Healthcare Worldwide agencies include Caudex Medic...
(Date:11/21/2008)... 21 Symmetry Medical Inc...f products to the global orthopedic device industr...Brian S. Moore, President and Chief Executive Offi...hief Financial Officer, are scheduled to present a...ence at The New York Palace Hotel on Wednesday, De...
Breaking Medicine News(10 mins):Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4
... known as metabolic syndrome is able to predict ty... // Metabolic syndrome has been shown to lead to ...rt disease. Metabolic syndrome includes looking at...ucose and blood pressure.Metabolic syndrome has tw...
...may be present early in life, say researchers. A n...mass index and C-reactive protein levels in childr...cular disease in adults. Researchers analyzed data...Nutrition Examination Survey, which included 1,479...
...n and women, age 55 and older researchers used mag...n size, infarcts and white matter lesions, which a...f stroke and to study if a link existed between lo... decrease in brain size of middle-aged adults. As ...
...sumption, in exchange for an increase in juice and...avities. The study investigators note a trend of c...rinks and less milk. They theorized this would lea...early 700 children aged 1 through 5 years. The chi...
Other Medicine News:
(Date:11/21/2008)... Ikaria Holdings, Inc. today announ...Year by the New Jersey Technology Council (NJTC), ...es business support, networking opportunities, inf... their leaders. Ikaria earned the award based on c...duct/service provision. , , "We are delight...
(Date:11/20/2008)... PHILADELPHIA, Nov. 20 Gl...the United States Food and Drug Administration (FD...ltrombopag) for the treatment of thrombocytopenia ...bocytopenic purpura (ITP) who have had an insuffic...or splenectomy. The approval is a significant mile...
(Date:11/20/2008).... 20 Bionovo, Inc.,(Nas...esults from the Phase 1B,clinical trial of their ...,cancer, BZL101, at the Society for Integrative O...ta, Georgia. The Company,s oral presentation was ...esented as a part of the Best of the,SIO Session ...
(Date:11/20/2008)...wire-FirstCall/ -- PAREXEL International Corporati...utical services provider, today announced that it ...latory consulting and clinical research capabiliti...now has locations throughout five important biopha...nclude Argentina, Brazil, Chile, and Mexico. This ...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Phreesia Launches at DEMOfall 07 1809 1Phreesia Launches at DEMOfall 07 1809 2Phreesia Launches at DEMOfall 07 1809 3Longs Drugs Announces Immunization Program for the 2007 2008 Flu Season 1807 1Longs Drugs Announces Immunization Program for the 2007 2008 Flu Season 1807 2Longs Drugs Announces Immunization Program for the 2007 2008 Flu Season 1807 3Kensey Nash Announces 2425 Million Stock Repurchase Program 1805 1Kensey Nash Announces 2425 Million Stock Repurchase Program 1805 2Kensey Nash Announces 2425 Million Stock Repurchase Program 1805 3Kensey Nash Announces 2425 Million Stock Repurchase Program 1805 4Kensey Nash Announces 2425 Million Stock Repurchase Program 1805 5BioCryst to Present at UBS 2007 Global Life Sciences Conference 776 1BioCryst to Present at UBS 2007 Global Life Sciences Conference 776 2BioCryst to Present at UBS 2007 Global Life Sciences Conference 776 3
...lia — 19 April 2007- Biota Holdings,Limited ...raminidase inhibitor (LANI), CS8958, an anti-influ...ess against the avian flu virus,H5N1; ,2. complete...s approval to commence comparable studies in the,U...yo, overnight announced,that laboratory ,studies h...
... 2007 /PRNewswire/ -- Addex Pharmaceuticals,announ... proof of,concept trial with its lead compound ADX...d its primary objective, the absence of,pain at 2 ... and,also showed trends towards improvement in pai...other time points. ADX10059 has,already recently d...
Other Medicine Technology:LANI completes Phase I in Japan and to commence Phase I in UK 2LANI completes Phase I in Japan and to commence Phase I in UK 3LANI completes Phase I in Japan and to commence Phase I in UK 4Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 2Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 3Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 4
Paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
The Omni-Flex System provides the capability to change frame arms in the middle of surgery while retaining exposure with tension on the incision. The system is also strong enough to be stable for lar
These retractors, made of rugged Noryl® resin, are pre-sterilized and packaged singly in double peel-pouches for easy delivery to the sterile surgical field.
Pipetman Concept is a revolutionary motorized electronic pipette. Conceived with simplicity and flexibility in mind, Pipetman Concept features exclusive multifunction characteristics and a direct pip
Medicine Products: